Printer Friendly

AFFYMAX RECEIVES $2.2 MILLION NIH HUMAN GENOME GRANT

 AFFYMAX RECEIVES $2.2 MILLION NIH HUMAN GENOME GRANT
 PALO ALTO, Calif., Oct. 14 /PRNewswire/ -- Affymax Research


Institute announced today that it has received a three-year research grant for $2.2 million from the National Institutes of Health. The grant will fund work on the application of Affymax VLSIPS(TM) chip technology to DNA sequencing.
 Under the grant, Stephen Fodor, Ph.D., director of physical sciences at Affymax and the grant's principal investigator, will work to develop novel DNA sequencing methods. VLSIPS is uniquely suited to the creation of large arrays of single-stranded DNA. Through a technique called sequencing by hybridization, target DNA sequences can be identified by their binding to complementary strands on the chip. Increasing DNA sequencing productivity is a critical challenge for the success of the Human Genome Project, an effort aimed at determining the composition of the human genome.
 "We believe that Affymax's VLSIPS technology will play an important role in the determination of nucleic acid structure, in the Human Genome Project and the in the diagnosis of genetic disease," stated Fodor.
 "As a result of the Human Genome Project, there will be expanding opportunities for products addressing the clinical diagnosis of genetic disease. We have formed a new subsidiary, Affymetrix, to commercialize the diagnostic applications of VLSIPS," stated John D. Diekman, Ph.D., president and chief operating officer of Affymax.
 Affymax N.V. (NASDAQ: AFMXF), a Netherlands corporation headquartered in Amsterdam, is developing new technologies to accelerate the pace of drug discovery. Affymax is applying these technologies across a broad range of diseases to discover and develop products independently and in collaboration with established pharmaceutical companies. The majority of the company's research and development activities are performed by its wholly owned subsidiary, Affymax Research Institute, located in Palo Alto.
 -0- 10/14/92 R
 /CONTACT: Diana E. Kapp of Affymax, 415-496-2300/
 (AFMXF) CO: Affymax Research Institute; Affymax N.V.; Affymetrix;
 National Institutes of Health ST: California IN: MTC SU:


SG-TM -- SJ002 -- 9809 10/14/92 11:25 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 14, 1992
Words:333
Previous Article:SC BANCORP POSTS THIRD QUARTER PROFIT
Next Article:KOCH REFINING COMPANY SPONSORS YOUNG ENTREPRENEURS OF MINNESOTA
Topics:


Related Articles
AFFYMAX RECEIVES $2.2 MILLION NIH HUMAN GENOME GRANT
AFFYMETRIX APPOINTS TOP MANAGEMENT
AFFYMAX REPORTS THIRD QUARTER RESULTS
Industry Watch : Research and Development.
Genomics.
Microbiome Project to study human bacteria systems.
NHGRI Funds Next Step in Understanding Biological Roots of Common Diseases.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters